Investor Relations

Introduction

Current treatment options for opioid and other forms of addiction do not work for most people. What’s missing is the ability to fast track the withdrawal process. Ibogaine – a molecule found in Tabernanthe iboga and other plants – offers the opportunity for a rapid detox. In combination with an effective therapeutic setting, ibogaine offers the opportunity to live free from addiction. Our goal is to provide safe, effective and affordable ibogaine treatment internationally this decade.

Why did we go public? To enable public participation in an ibogaine-focused company incorporating: 

Market Data

Stock Quote:

We are now a publicly traded company listed on the Toronto Stock Exchange Venture, you can find us at TSX.V: IBO.

Historical Chart:

Market Overview:

Recent News:

Investor Presentation

Milestones

.01

Clinical Trials Application to Commence

.02

Conventional Detox Clinics in Operation in 2021

.03

Phase 2 Clinical Trials begin in 2022

.04

 Phase 3 Clinical Trials begin in Q3 2022

 Our balance of medical expertise, clinic operations, and capital markets relationships puts us on a path for success.

Board of Directors

Chief Ian Campbell

Chief Ian Campbell, MBA

Chairman

Dr. Alberta Sola

Dr. Alberta Sola, Ph.D

CoFounder & Director

Marilyn Mauritz

Marilyn Mauritz

Director

Robert Turner, MBA

Robert Turner, MBA

Director

Connect with Us

OUR WHY

TEAM

UNIVERSAL IBOGAINE
NEWS